STERIS plc (STE) will report its fiscal fourth-quarter 2026 results after the close on May 11, and the setup is more about execution than surprise. What investors need from the Q4 report is evidence that STERIS can land within its full-year earnings range and explain how much tariff pressure may linger beyond the fiscal year-end.
STERIS’ fiscal year ends in March, so Q4 FY2026 covers January through March 2026. Wall Street is looking for adjusted EPS of about $2.89 on revenue of roughly $1.59 billion. That would imply another quarter of year-over-year growth, but the bigger issue is whether the company can translate healthy demand in Healthcare and Applied Sterilization Technologies into enough margin resilience to close the year cleanly.
Related Coverage
The latest reported quarter provided a reasonably solid base. In Q3 FY2026, STERIS said revenue rose 9% year over year to $1.1 billion, while adjusted EPS increased to $2.53. The company also maintained full-year adjusted EPS guidance of $10.15 to $10.30 and said free cash flow for the first nine months reached a record $737.6 million. Those figures matter because they suggest underlying demand remains intact even as tariffs and product mix continue to pressure profitability.
What Wall Street Expects in Q4 FY2026
Consensus Adjusted EPS and Revenue Targets
Heading into STERIS plc’s (NYSE: STE) Q4 FY2026 earnings report, scheduled for release on May 11, 2026, after market close, the analyst community has coalesced around a set of estimates that reflect both the company’s demonstrated growth trajectory and the moderating pace expected in the final quarter of the fiscal year. The Zacks Consensus Estimate for Q4 FY2026 adjusted (non-GAAP) EPS stands at approximately $2.89 per share, representing a year-over-year increase of approximately 5.5% from the Q4 FY2025 adjusted EPS of $2.74 per share. On the revenue side, the consensus estimate for Q4 FY2026 is approximately $1.5946 billion, implying year-over-year growth of approximately 7.9% from the comparable prior-year quarter.
These estimates have remained notably stable in the 30 days leading up to the report, with the adjusted EPS consensus holding at $2.89 per share without revision. That stability reflects a degree of analyst confidence in STERIS’s near-term visibility, supported by recurring revenue streams, a strong capital equipment backlog, and management’s consistent reaffirmation of full-year FY2026 guidance throughout the year.
Metric
Q4 FY2026 Estimate
Q4 FY2025 Actual
YoY Change
Adjusted (Non-GAAP) EPS
~$2.89
$2.74
+5.5%
Revenue
~$1.5946 billion
~$1.478 billion
+7.9%
Beat History and Earnings Surprise Track Record
STERIS’s recent earnings history provides important context for interpreting the Q4 FY2026 consensus. Over the trailing four quarters, STERIS beat the adjusted EPS consensus estimate in three quarters and matched it in one, producing an average positive earnings surprise of approximately 2.61%. Most recently, in Q3 FY2026 reported on February 4, 2026, STERIS posted adjusted (non-GAAP) EPS of $2.53, which matched the consensus estimate precisely, while total revenue of approximately $1.5 billion grew 9% year over year.
This track record suggests that while outright beats are common, the Q4 FY2026 consensus of $2.89 per share already incorporates a degree of conservatism. Analysts have not revised estimates upward despite three consecutive quarters of 9% revenue growth, which may reflect management’s own cautious commentary during the Q3 FY2026 earnings call, where executives signaled that Q4 would face tougher year-over-year comparisons, particularly in the Applied Sterilization Technologies (AST) segment and Healthcare services.
Implied Q4 Adjusted EPS Relative to Full-Year Guidance
A straightforward arithmetic check on STERIS’s FY2026 adjusted EPS guidance provides a useful benchmark against which to evaluate the Q4 FY2026 consensus. Through the first three quarters of FY2026, STERIS has cumulatively reported adjusted (non-GAAP) EPS of approximately $7.30 per share, based on Q1 through Q3 FY2026 results. STERIS’s maintained FY2026 adjusted EPS guidance range of $10.15 to $10.30 per share implies a midpoint of approximately $10.225 per share.
Subtracting the three-quarter cumulative total of $7.30 from the guidance midpoint of $10.225 yields an implied Q4 FY2026 adjusted EPS of approximately $2.93 per share — modestly above the current consensus estimate of $2.89 per share. This gap of approximately $0.04 per share is narrow but meaningful: it suggests that the consensus, as currently set, would place full-year FY2026 adjusted EPS slightly below the guidance midpoint, closer to the lower end of the $10.15 to $10.30 range. Investors and analysts will therefore be watching whether STERIS can close that gap and deliver at or above the midpoint, which would require a modest beat relative to the $2.89 per share consensus.
Metric
Value
Q1–Q3 FY2026 Cumulative Adjusted EPS
~$7.30
FY2026 Guidance Midpoint
~$10.225
Implied Q4 FY2026 Adjusted EPS (to hit midpoint)
~$2.93
Q4 FY2026 Consensus Adjusted EPS Estimate
~$2.89
Gap (Midpoint vs. Consensus)
~$0.04
Segment-Level Revenue Consensus
Beyond the headline figures, analysts have also established segment-level revenue expectations for Q4 FY2026 that reflect differentiated growth rates across STERIS’s three operating segments.
Segment
Q4 FY2026 Revenue Estimate (YoY Growth)
Healthcare
+7.5% year over year
Applied Sterilization Technologies (AST)
+7.9% year over year
Life Sciences
+10.8% year over year
The Life Sciences segment carries the highest expected growth rate at 10.8% year over year, driven by anticipated continuation of the consumables recovery and a return of capital equipment shipments that began in Q3 FY2026. The AST segment is expected to grow 7.9% year over year, supported by stable medical device volumes, bioprocessing demand, and favorable currency dynamics, though management has flagged tougher year-over-year comparisons in this segment for Q4. The Healthcare segment, STERIS’s largest by revenue, is expected to grow 7.5% year over year, underpinned by recurring service revenues, consumables demand, and continued capital equipment backlog conversion.
Why Q4 FY2026 Matters for Fiscal Year Completion
Q4 FY2026 carries extra weight because it closes the fiscal year. The report will determine whether STERIS lands within, at, or above its maintained FY2026 adjusted EPS guidance range of $10.15 to $10.30 per share. Full-year revenue growth expectations will also be judged against the quarter’s delivery, especially after management kept its annual framework intact through Q3.
Just as important, investors will listen for management’s first read on the next fiscal year. If STERIS sounds confident that pricing, productivity actions, and mix can offset at least part of the tariff pressure, the market may look past a routine Q4 result. If commentary suggests margin repair will take longer, expectations for the next fiscal year could reset lower.
Key Signals for Investors
The Q4 FY2026 consensus adjusted EPS estimate of approximately $2.89 per share sits approximately $0.04 below the implied level needed to reach the FY2026 guidance midpoint of $10.225, meaning a modest beat would be required for STERIS to land at the center of its own guidance range.
Analyst sentiment is broadly constructive at a Moderate Buy average with a price target of approximately $275.
Life Sciences segment revenue is expected to grow the fastest among the three segments at 10.8% year over year in Q4 FY2026, making it a key variable to watch given its recovery trajectory from prior-year weakness.
Management’s first comments on the next fiscal year will matter more than a routine beat or miss because investors want to know how quickly margin pressure can ease.
Tariff headwinds of approximately $55 million for full-year FY2026 remain a margin watch item, and any commentary on mitigation progress will be closely scrutinized by investors assessing the durability of STERIS’s margin profile.
